Andrea Eleazar, MHS

Axillary RFS at 3 years was noninferior with less vs more invasive staging procedures in node-negative breast cancer after neoadjuvant chemotherapy.

Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

Sac-TMT bested chemotherapy in terms of PFS in previously treated HR+, HER2– metastatic breast cancer.

The addition of durvalumab to FLOT prolonged overall survival vs FLOT alone in resectable gastric/gastroesophageal junction adenocarcinoma.